Co-Diagnostics, which is commercializing diagnostic equipment for DNA tests, announced terms for its IPO on Friday.
The Salt Lake City, UT-based company plans to raise $9 million by offering 1.3 million shares at a price range of $6.35 to $6.75. At the midpoint of the proposed range, Co-Diagnostics would command a fully diluted market value of $75 million.
Co-Diagnostics was founded in 2013 and it plans to list on the Nasdaq under the symbol CODX. WallachBeth Capital and Network 1 Financial Securities are the joint bookrunners on the deal. It is expected to price during the week of June 26, 2017.
